Etranacogene Dezaparvovec-drlb (Hemgenix) — CPB 1023 | AETNA Coverage Update

Aetna modified CPB 1023 for etranacogene dezaparvovec-drlb (Hemgenix), effective September 26, 2025. Here's what billing teams need to do.

Aetna, a CVS Health company, updated its Hemgenix coverage policy under CPB 1023 Aetna system, governing the one-time gene therapy for Hemophilia B. The primary billing code is HCPCS J1411 (injection, etranacogene dezaparvovec-drlb, per therapeutic dose). This is one of the most financially significant therapy categories your billing team will touch — a single infusion carries a list price exceeding $3.5 million, which means a single claim denial or failed prior authorization has catastrophic revenue impact.

Quick-Reference Table

Aetna Hemgenix Coverage Criteria and Medical Necessity Requirements 2025

The Aetna Hemgenix coverage policy requires precertification for every member, every time. There are no exceptions based on plan design — if your patient has commercial Aetna coverage, you need prior authorization before administration.

To request precertification, call (866) 752-7021 or fax (888) 267-3277. For Statement of Medical Necessity forms, go directly to Aetna's Specialty Pharmacy Precertification page. Don't wait on this — gene therapy authorizations take longer than standard PA timelines, and there is no retroactive coverage path for a missed precertification on a therapy at this price point.

The primary covered code is J1411. Every supporting lab, imaging, and infusion service billed alongside J1411 must tie back to documented medical necessity. The policy references a wide range of diagnostic workup codes — liver function panels, coagulation studies, Factor IX assays — all of which feed the medical necessity record for this therapy. Build your documentation before you bill, not after.

For Medicare members, this CPB does not apply. Aetna directs those cases to its Medicare Part B criteria separately. If your patient mix includes Medicare Advantage through Aetna, verify which criteria set governs — commercial CPB 1023 or the Part B pathway — before you build the PA packet.

The GCIT Network Requirement Is the Most Important Sentence in This Policy

Hemgenix must be administered at an Aetna Institutes® Gene Based, Cellular and Other Innovative Therapy (GCIT®) Network facility. This applies unless the member's specific health plan has opted out of this requirement — which is rare.

Billing J1411 from a facility that is not GCIT-designated will result in claim denial, regardless of whether the precertification was approved. The authorization and the site requirement are two separate gates. Passing one does not open the other.

Verify your facility's GCIT designation status at Aetna's Institutes GCIT Designated Networks page before you schedule the infusion. If you're a specialty pharmacy or infusion center that has not applied for GCIT designation, that process starts with Aetna's network contracting team — not with your standard credentialing contact.

Coverage Indications at a Glance

Aetna Hemgenix Billing Guidelines and Action Items 2025

1. Confirm GCIT Network Status — Do This First

Before anything else, verify the infusion site's GCIT designation on Aetna's network page. Do this before the patient is scheduled, before the PA is filed, and before any contracts are signed. This is the single most common failure point in gene therapy billing — the site assumes network status without confirming it.

2. Submit Precertification Before Administration

Call (866) 752-7021 or fax the SMN form to (888) 267-3277. Build a complete clinical package: Factor IX activity levels, history of inhibitor development, liver function results (CPT 80076, 84450, 84460), hepatic imaging (CPT 76981 or 91200), HIV status (CPT 87536), and hepatitis serology (ICD-10 B18.1, B18.2 as applicable). Aetna will not approve a PA packet with gaps in this workup.

3. Code J1411 Correctly — One Therapeutic Dose

HCPCS J1411 is billed per therapeutic dose. Hemgenix is a one-time therapy. You will bill J1411 once, and it needs to match exactly what was authorized. Any discrepancy between the authorized dose and the billed dose triggers a review — and at this price point, that review will be thorough.

4. Bill Infusion Administration Codes with J1411

Pair J1411 with the appropriate IV infusion codes: CPT 96365 (initial infusion, up to one hour), CPT 96366 (each additional hour), CPT 96367 (additional sequential infusion), and CPT 96368 (concurrent infusion) as applicable to the actual infusion session. These codes must reflect the actual infusion record — duration, sequence, and concurrent medications.

5. Build Out the Diagnostic Billing for Pre- and Post-Treatment Monitoring

The policy references an extensive list of labs and imaging codes. Use them. Billing CPT 85250 (Factor IX clotting assay), CPT 85335 (factor inhibitor test), CPT 81238 (F9 full gene sequence), CPT 86361 (absolute CD4 count), and the hepatic panel codes creates the medical necessity paper trail that supports reimbursement and survives post-payment audit.

6. Verify Plan-Level Opt-Outs for the GCIT Requirement

Some Aetna plan designs have elected not to require GCIT network administration. Check the member's specific plan documents — not just their Aetna ID card. If the plan has opted out, you have more site flexibility, but precertification still applies. Document which plan design governs before you proceed.

7. Separate Medicare Advantage Cases from Commercial Cases

If you see Aetna Medicare Advantage members with Hemophilia B, CPB 1023 does not govern their coverage. Aetna routes Medicare Part B criteria separately. Filing a commercial PA for a Medicare Advantage member — or billing under commercial criteria — creates a coverage mismatch that produces a claim denial and a compliance problem. If you're unsure which pathway governs a specific member, talk to your compliance officer before the effective date of service.

CPT, HCPCS, and ICD-10 Codes for Hemgenix Under CPB 1023

Covered HCPCS Code (When Selection Criteria Are Met)

Other HCPCS Codes Related to This Policy

These codes support the clinical workup, perioperative management, or alternative Factor IX therapies. They are not covered as the primary therapy under CPB 1023, but may be billed as related services.

CPT Codes Related to This Policy

Key ICD-10-CM Diagnosis Codes

The hepatic and hepatitis ICD-10 codes matter here because liver health is a direct candidacy criterion for Hemgenix. Patients with significant hepatic disease may not qualify. Your pre-authorization packet needs to address hepatic status explicitly — not just Factor IX levels.